Mentor Capital Sees a Shift to Public Acceptance of Dendreon-like Cancer Immunotherapy Treatments and Companies in Fox New

SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) notes the featuring of Dendreon's (NASDAQ:DNDN) Provenge prostate cancer vaccine on Fox News is a certain sign that cancer immunotherapy has come to a point of popular acceptance in the public mind. One year ago only biotech investment reviews and medical journal reports followed pioneering Cancer Immunotherapy Index member Dendreon as it climbed 1,000% in forty-five days.

Dendreon continues to lead the Index in the FDA approval race. Mentor Capital anticipates a positive FDA announcement for Provenge to be reported at month-end. This will be a significant milestone not only for Dendreon, but also for the several Dendreon-like companies in the Cancer Immunotherapy Index that use the same approach. Different cancers are fought by attacking their different cancer proteins, but the general mobilization of the human immune system is similar.

In addition to Dendreon's possible pending treatment for prostate cancer, other Cancer Immunotherapy Index Companies are also pursuing treatments targeting cancer stem cells or brain, breast, melanoma and other cancer immunotherapies. Quite possibly, two or three markets of equal or greater size to Dendreon's will evolve from the Cancer Immunotherapy Index companies, simply because there are two or three times the occurrence of cancer in the other cancer types that those companies are working on.

Perhaps because the relative opportunity favors the smaller Index companies, Dendreon's extraordinary annual rate of stock price appreciation, including today's early price jump, is only 100% growth, compared to the overall Index annualized rate of growth of 125%, since Index formation July 10, 2009.

The Mentor Capital Cancer Immunotherapy Index includes: Dendreon; Provectus Pharmaceuticals, Inc. (OTCBB:PVCT); Immunocellular Therapeutics, Ltd. (OTCBB:IMUC); Oncothyreon (NASDAQ:ONTY); Antigenics (NASDAQ:AGEN); Biovest International (BVTI.PK); Celldex Therapeutics (NASDAQ:CLDX); Northwest Biotherapeutics (OTCBB:NWBO); CEL – SCI Corp. (AMEX:CVM); and Generex Biotechnology (NASDAQ:GNBT) as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, and Quantum Immunologics, Inc. a private company.

Mentor Capital, Inc. invests in all companies in the Cancer Immunotherapy Index and significantly overweights its positions in those companies it views with the greatest medical and financial promise. The Index company summaries can be tracked through updates of the Cancer Immunotherapy Index presented at www.MentorCapital.com.

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.



CONTACT:

Mentor Capital, Inc.
Chet Billingsley, CEO
760-788-4700

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Other Consumer  Health  Biotechnology  Genetics  Oncology  Pharmaceutical  Professional Services  Finance  Research  FDA  Consumer  Science

MEDIA:

Logo
 Logo

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.